LIVER PANCREAS DISEASE CENTER
LIVER AND PANCREAS
DISEASE CENTER
Patients in Texas and beyond who have liver, bile
duct or pancreas cancer can utilize one of the few
facilities in the nation solely dedicated to treating
their condition. Providing precise diagnoses and
individually tailored treatment plans quickly and
efficiently is the goal of the Liver and Pancreas
Disease Center (LPC) at Baylor Dallas and
Baylor Scott & White – Fort Worth.
“Providing all of the resources a patient needs
to determine his or her specific diagnosis and
treatment is achieved through a center without
walls,” said Robert M. Goldstein, MD, surgical
director, Liver and Pancreas Disease Center at
Baylor Dallas. “With one phone call from the
patient’s referral source, we coordinate testing and
consults before the patient walks through the door.
Patient convenience is at the heart of the Liver and
Pancreas Disease Center, and we are often able to
determine the course of care from the very first visit.”
One primary example of timely, coordinated
care can be found in imaging. If the patient
requires radiologic workup, it can be completed
quickly in the morning, read by a radiologist and
reviewed with the patient that same afternoon.
“About 80 to 90 percent of the time, treatment
recommendations are made the same day,” said
Dr. Goldstein. “The other 10 percent are referred
to the liver or pancreas tumor boards for review
and discussion before coming to an agreement
on the best course of treatment.” This prompt,
coordinated approach is reassuring to patients.
These once untreatable liver, pancreas and bile
duct (HPB) diseases are now routinely addressed
by a multidisciplinary team of experts, and the
9,533 patients have received
treatment since the Liver
and Pancreas Disease
Center opened in 1998.
2,416 clinic visits in 2016
950 new patients with a
total of 2,416 clinic
visits in 2016
outcomes are impressive. High-risk, complex
patients who come to the LPC with tumors, cysts
or other complications in the liver, pancreas or bile
ducts have access to progressive treatments, such
as two-stage liver resections, ablative therapies,
pinpoint beam radiation and transplantation.
More than 9,533 patients have received treatment
for their malignant or benign HPB disease since
the Liver and Pancreas Disease Center opened
in 1998. The center saw 950 new patients
with a total of 2,416 clinic visits in 2016.
To accommodate the growth in patient visits,
two surgeons, including one based full-time
in Fort Worth, joined the LPC team. Multiple
research studies and clinical trials were ongoing in
2016, offering this very difficult group of patients
the opportunity for novel treatment options and
new possibilities.
13